0%
Print report
Variant interpretation report

BRCA2 c.598A>G, p.Thr200Ala

NM_000059.4:c.598A>G NP_000050.3:p.(Thr200Ala) Missense · exon 7 View identifiers
Classification
Uncertain significance

Variant description:

The BRCA2 NM_000059.4:c.598A>G (NP_000050.3:p.(Thr200Ala)) missense variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About BRCA2

BRCA2 encodes a DNA repair protein that maintains genome stability by repairing double-strand breaks through homologous recombination and by protecting DNA replication forks. It acts as a tumor suppressor, and inherited loss-of-function changes cause hereditary breast and ovarian cancer syndrome, with elevated lifetime risks of breast, ovarian, prostate, and pancreatic cancers; biallelic changes cause Fanconi anemia complementation group D1. Reduced or altered BRCA2 activity is implicated in multiple tumor types, and PARP inhibitors are an approved treatment for BRCA2-associated ovarian and breast cancers.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen BRCA2 VCEP v1.2. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 0 Benign evidence criteria: 1
Pathogenic criteria applied · 0

No pathogenic criterion marked as applied in the recorded assessment.

Benign criteria applied · 1
BP1Strong
BP1 · strong

Met at strong: residue 200 is outside aa 10-40 and 2481-3186, with SpliceAI maximum delta 0.073 meeting the ≤0.1 threshold.

Recorded classification: Uncertain significance

VUS: BP1 (strong) is the only met criterion and does not satisfy an ENIGMA benign or likely benign combination by itself.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
13 / 1,611,912 alleles

gnomAD v4.1: 13 / 1,611,912 alleles. Recorded AF 8.06496e-06. Recorded homozygote count 0.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.225 recorded score

Recorded REVEL score: 0.225. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
ClinVar submissions
5 reported laboratory submissions

5 Uncertain significance. ClinVar API review status: criteria provided, multiple submitters, no conflicts.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen BRCA2 VCEP v1.2, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 5 not met · 9 not assessed · 13 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

All three requested consequence/LOF criteria are not applicable under the ENIGMA BRCA2 v1.2 rules because the variant is a missense substitution and none of these criteria governs ordinary missense variants.

The only variant-specific phenotype likelihood value located in the governing VCEP materials is Li et al. 2020's clinical-history LR of 1.277769323983238 for BRCA2 c.598A>G; it is below PP4's pathogenic threshold and above BP5's benign threshold.

PS4 remains not assessed because no variant-specific case-control dataset with the VCEP-required OR, p-value, and confidence interval was available.

PP5 and BP6 are not applicable because the ENIGMA specification explicitly instructs reviewers not to use them.

Met · 1

BP1 StrongVCEPMet at strong: residue 200 is outside aa 10-40 and 2481-3186, with SpliceAI maximum delta 0.073 meeting the ≤0.1 threshold. Details ▾Hide ▴
Reasoning

NM_000059.4:c.598A>G is a missense variant producing p.Thr200Ala at residue 200. The ENIGMA-defined clinically important BRCA2 domains are PALB2 binding aa 10-40 and DNA binding aa 2481-3186; residue 200 is outside both. Case evidence reports SpliceAI maximum delta 0.073, which is at or below the VCEP BP1 no-splicing threshold of 0.1. Therefore BP1_Strong is met.

VCEP rule
Apply BP1_Strong for silent substitution, missense or in-frame insertion, deletion or delins variants outside a (potentially) clinically important functional domain AND no splicing predicted (SpliceAI ≤0.1). Missense prediction not applicable.
Evidence considered
  • Case normalization: NM_000059.4:c.598A>G, NP_000050.3:p.(Thr200Ala), missense.
  • VCEP domain definition: BRCA2 PALB2 binding domain aa 10-40 and DNA binding domain aa 2481-3186; residue 200 is outside both.
  • SpliceAI Lookup: maximum delta score 0.073.
  • Specifications_V1.2_2024-11-18.docx, BP1_Strong application: variant outside a potentially clinically important functional domain and no splicing predicted (SpliceAI ≤0.1).
Sources

Not met · 5 · evaluated, threshold not reached

PS1 VCEPNot met: no previously classified pathogenic variant producing the same p.Thr200Ala substitution was identified for the PS1 comparator requirement. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, but the governing ENIGMA material provides no previously classified pathogenic variant producing the same p.Thr200Ala amino-acid change. The exact target variant was found in the ENIGMA clinical-history likelihood table, but that row reports log10(LR)=0.1064524576067924, N_Probands=1, LR=1.277769323983238 and is not a same-amino-acid pathogenic comparator. The governing PS1 rule therefore is not satisfied.

VCEP rule
PS1 may be applied for a variant predicted to lead to the same missense substitution as a known pathogenic variant that is due to a different nucleotide change. Use at moderate weight if reference variant is classified as likely pathogenic. Both (likely) pathogenic variant and variant under assessment should have no predicted/confirmed effect on mRNA splicing. (Likely) pathogenic variant should be assigned classification using VCEP specifications.
Evidence considered
  • Target variant normalization: NM_000059.4:c.598A>G, NP_000050.3:p.(Thr200Ala) / p.(T200A), missense.
  • SupplementaryTables_V1.2_2024-11-18.xlsx, ST7 Reference Set Vts: no c.598A>G, p.Thr200Ala, or p.T200A row was found; the target is not established there as a pathogenic comparator.
  • Specifications_V1.2_2024-11-18.docx, PS1 rule: same amino-acid change as a previously established pathogenic variant may support PS1; no such comparator was found.
  • PMID_31853058_BRCA2_clinical_history_LR.xlsx, Sheet1 exact match row BRCA2 c.598A>G: LOG(LR)=0.1064524576067924, N_Probands=1, LR=1.277769323983238; this is clinical-history likelihood evidence for the target, not a same-amino-acid pathogenic reference variant.
Still missing
  • No same-amino-acid pathogenic comparator was found in SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, or Specifications_Table4_V1.2_2024-11-18.xlsx.
Sources
PP3 VCEPNot met: SpliceAI maximum delta 0.073 is below the ENIGMA PP3 splicing threshold of 0.2 for missense variants. Details ▾Hide ▴
Reasoning

The variant is missense at p.Thr200Ala and lies outside the VCEP-defined BRCA2 clinically important domains (PALB2-binding aa 10-40 and DNA-binding aa 2481-3186), so the PP3 protein-impact route does not apply. The applicable PP3 splicing route covers missense variants irrespective of domain location, but requires SpliceAI >=0.2; the observed maximum delta score is 0.073 (DS_DG 0.073), therefore the splicing prediction does not meet PP3. No pre-assigned PP3 code or variant-level entry was found for c.598A>G, p.Thr200Ala, or p.T200A in SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, or PMID_22505045_Houdayer_2012_HumMutat.pdf.

VCEP rule
Do not apply PP3 if PVS1 is met at any strength. ... Apply PP3 for missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain and predicted impact via protein change (BayesDel predicted Impact). ... Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions.
Evidence considered
  • NM_000059.4:c.598A>G is a missense variant encoding NP_000050.3:p.(Thr200Ala), outside the VCEP-defined BRCA2 PALB2-binding domain aa 10-40 and DNA-binding domain aa 2481-3186; the PP3 protein-impact route therefore does not apply.
  • SpliceAI lookup for NM_000059.4:c.598A>G: DS_AG=0.053, DS_AL=0.000, DS_DG=0.073, DS_DL=0.001; maximum delta score=0.073, below the VCEP PP3 threshold of >=0.2 for predicted splicing.
Still missing
  • No variant-level PP3 pre-assignment was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-level PP3 entry was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-level PP3 entry was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-level PP3 entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.
Sources
BA1 VCEPNot met: gnomAD v4.1 grpmax FAF is 6.16e-06, below the ENIGMA BA1 threshold of 0.001, with no non-cancer v2.1/v3.1 observation. Details ▾Hide ▴
Reasoning

The ENIGMA VCEP requires BA1 when maximum filter allele frequency exceeds 0.001 in a non-founder population, using the specified non-cancer gnomAD v2.1 exome and/or v3.1 genome datasets. The variant is absent from gnomAD v2.1 non-cancer and v3.1 non-cancer; the available gnomAD v4.1 data show grpmax FAF 6.16e-06 (13/1,611,912 total alleles; 0 homozygotes), well below 0.001. Therefore BA1 is not met. The four governing VCEP reference files were searched for c.598A>G, p.Thr200Ala, and p.T200A; no variant-specific entry was found.

VCEP rule
Filter allele frequency (FAF) is above 0.1% (FAF > 0.001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • ENIGMA CSPEC BA1 rule: maximum filter allele frequency above 0.001 in gnomAD v2.1 non-cancer exomes and/or gnomAD v3.1 non-cancer genomes, in a non-founder population.
  • gnomAD v2.1 non-cancer: absent; gnomAD v3.1 non-cancer: absent.
  • gnomAD v4.1: total AF 8.06496e-06, 13/1,611,912 alleles, 0 homozygotes; highest population AF 1.10359e-05 in European (non-Finnish); grpmax FAF 6.16e-06.
  • The four on-record VCEP files were searched under c.598A>G, p.Thr200Ala, and p.T200A; none contained a variant-specific row.
Still missing
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in HUMU-40-1557-s001.xlsx.
Sources
BS1 VCEPNot met: gnomAD v4.1 grpmax FAF is 6.16e-06, below the ENIGMA BS1 Supporting lower boundary of 0.00002. Details ▾Hide ▴
Reasoning

The ENIGMA VCEP assigns BS1 Strong when maximum filter allele frequency exceeds 0.0001 and BS1 Supporting when it is greater than 0.00002 and at most 0.0001, using non-cancer gnomAD v2.1 exomes and/or v3.1 genomes in non-founder populations. The variant is absent from the specified non-cancer v2.1 and v3.1 datasets, and the available gnomAD v4.1 grpmax FAF is 6.16e-06, below 0.00002. Thus neither BS1 Strong nor BS1 Supporting is met. The four governing VCEP reference files were searched for c.598A>G, p.Thr200Ala, and p.T200A; no variant-specific entry was found.

VCEP rule
Filter allele frequency (FAF) is above 0.01% (FAF > 0.0001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details. ... Filter allele frequency (FAF) is above 0.002% (FAF > 0.00002) and less than or equal to 0.01% (FAF <= 0.0001) in gnomAD v2.1 (non-cancer, exome only subset) and/or gnomAD v3.1 (non-cancer), non-founder population(s). See Appendix G for details.
Evidence considered
  • ENIGMA CSPEC BS1 rules: BS1 Strong requires FAF >0.0001; BS1 Supporting requires FAF >0.00002 and <=0.0001 in the specified non-cancer, non-founder gnomAD populations.
  • gnomAD v2.1 non-cancer: absent; gnomAD v3.1 non-cancer: absent.
  • gnomAD v4.1: grpmax FAF 6.16e-06, below 0.00002; 0 homozygotes.
  • The four on-record VCEP files were searched under c.598A>G, p.Thr200Ala, and p.T200A; none contained a variant-specific row.
Still missing
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in HUMU-40-1557-s001.xlsx.
Sources
BP5 VCEPNot met: Li et al. clinical-history LR 1.27777 does not satisfy the VCEP BP5 supporting inequality, 1.27777 ≤ 0.48? no. Details ▾Hide ▴
Reasoning

The ENIGMA clinical-history table contains BRCA2 c.598A>G with LOG(LR)=0.1064524576067924 and LR=1.277769323983238. The VCEP BP5 supporting rule requires LR ≤0.48, with stronger benign levels requiring still lower values. The required comparison is 1.277769323983238 ≤ 0.48? no; therefore BP5 is not met. This clinical-history LR is not in the VCEP's BP5 informative range.

VCEP rule
Use ONLY to capture combined LR against pathogenicity, based on multifactorial likelihood clinical data. ... BP5_VeryStrong – LR ≤0.00285:1 ... BP5_Strong - LR ≤0.05:1 ... BP5_Moderate - LR ≤0.23:1 ... BP5 - LR ≤0.48 to >0.23:1 ... Combined LR >0.48-1.00 is not informative (BP5 not applicable)
Evidence considered
  • Li et al. 2020 BRCA2 clinical-history LR table, exact row BRCA2 c.598A>G: LOG(LR)=0.1064524576067924, N_Probands=1, LR=1.277769323983238.
  • The VCEP BP5 rule states: BP5 - LR ≤0.48 to >0.23:1; stronger levels are BP5_Moderate - LR ≤0.23:1, BP5_Strong - LR ≤0.05:1, and BP5_VeryStrong - LR ≤0.00285:1.
  • Explicit threshold comparison: 1.277769323983238 ≤ 0.48? no.
Sources

Not assessed · 9 · no assessment recorded

PS3 VCEPNot assessed: no calibrated damaging protein assay result specific to c.598A>G or p.(Thr200Ala) was found in the governing VCEP sources. Details ▾Hide ▴
Reasoning

PS3 cannot be assessed from the available VCEP-governed evidence. The governing ENIGMA rule requires well-established in vitro or in vivo studies showing a damaging effect measured through protein, or mRNA and protein combined, and directs use of calibrated published assays in Table 9. Exact-variant searches for c.598A>G, p.Thr200Ala, and p.T200A found no row in Specifications_Table9_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, HUMU-40-1557-s001.xlsx, or SupplementaryTables_V1.2_2024-11-18.xlsx. Table 9 contains a different same-position variant, c.599C>T p.(Thr200Ile), and the extracted functional paper PMID:29988080 explicitly does not mention c.598A>G or p.(T200A); neither can be transferred to this variant. No calibrated damaging assay result specific to c.598A>G is therefore available to apply PS3.

VCEP rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect. Apply PS3 for assays measuring effect via protein only OR mRNA and protein combined. See Specifications Table 9 for code recommendations from calibrated published assays. Also see Figure1C and Appendix E for details.
Evidence considered
  • Specifications_Table9_V1.2_2024-11-18.xlsx, sheet Table9_BRCA12VCEP_specs: exact-notation searches for c.598A>G, p.Thr200Ala, and p.T200A returned no row; the table states that additional published assay results must be reviewed under Figure 1C before PS3 or BS3 application.
  • Specifications_Table9_V1.2_2024-11-18.xlsx, sheet Table9_BRCA12VCEP_specs: c.599C>T p.(Thr200Ile) is a different variant and is not evidence for c.598A>G p.(Thr200Ala).
  • PMID:29988080 paper_extracts entry: the mESC complementation, HDR, cisplatin, and PARP-inhibitor assay paper does not mention c.598A>G or p.(T200A), so it supplies no variant-specific damaging result.
  • The governing ENIGMA PS3 rule requires a well-established damaging functional study measured via protein or combined mRNA and protein; the required variant-specific calibrated result is unavailable.
Still missing
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx, the ENIGMA curated functional-assay table.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in HUMU-40-1557-s001.xlsx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • The available functional paper PMID:29988080 describes a BRCA2 assay but its extracted finding states that c.598A>G and p.(T200A) are not mentioned; no variant-specific assay result is available from that paper.
Sources
PS4 VCEPNot assessed: no variant-specific case-control counts or OR/p-value/95% CI were available to test the VCEP PS4 thresholds (OR ≥4; lower CI >2.0; p ≤0.05). Details ▾Hide ▴
Reasoning

The governing ENIGMA rule requires a case-control study with p-value ≤0.05, OR ≥4, and a lower confidence interval excluding 2.0. No variant-specific case-control counts, odds ratio, p-value, or confidence interval were found for c.598A>G/p.Thr200Ala/p.T200A in the searched ENIGMA SupplementaryTables_V1.2_2024-11-18.xlsx, HUMU-40-1557-s001.xlsx, or the available literature packet. The literature_pass.json packet has an empty ai_classified_papers list, and the available paper extracts do not report this variant. Therefore the criterion cannot be evaluated rather than being treated as absent evidence.

VCEP rule
The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls. ... Case-control studies; p-value ≤0.05 and OR ≥4 (lower confidence interval excludes 2.0).
Evidence considered
  • The VCEP SupplementaryTables file was searched for c.598A>G, p.Thr200Ala, and p.T200A; no matching variant row was found.
  • The VCEP HUMU-40-1557-s001 multifactorial table was searched for c.598A>G, p.Thr200Ala, and p.T200A; no matching variant row was found.
  • Available paper extracts for the literature packet did not report this exact variant; the literature_pass packet lists no ai_classified_papers.
Still missing
  • No c.598A>G, p.Thr200Ala, or p.T200A entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx; no case-control OR, p-value, or confidence interval is available there.
  • No c.598A>G, p.Thr200Ala, or p.T200A entry was found in HUMU-40-1557-s001.xlsx; no case-control counts or case-control LR are available there.
  • The literature_pass.json packet contains no ai_classified_papers for PS4, and the available paper extracts do not provide variant-specific PS4 case-control data.
Sources
PM2 VCEPNot assessed: the variant is absent from non-cancer gnomAD v2.1/v3.1, but required regional average read depth of at least 25 is unavailable. Details ▾Hide ▴
Reasoning

The ENIGMA VCEP permits PM2 Supporting only when the variant is absent from controls in the specified non-cancer gnomAD v2.1 exome and v3.1 genome datasets and the region has average read depth at least 25. The variant is reported absent from both specified non-cancer datasets, but the available evidence does not provide the required regional average read depth. Because the VCEP rule cannot be fully evaluated, PM2 is not assessed rather than applied. The four governing VCEP reference files were searched for c.598A>G, p.Thr200Ala, and p.T200A; no variant-specific entry was found.

VCEP rule
Absent from controls in an outbred population, from gnomAD v2.1 (non-cancer, exome only subset) and gnomAD v3.1 (non-cancer). Region around the variant must have an average read depth ≥25. See Appendix G for details.
Evidence considered
  • ENIGMA CSPEC PM2 rule: absent from controls in an outbred population in gnomAD v2.1 non-cancer exomes and gnomAD v3.1 non-cancer genomes, with average read depth at least 25.
  • gnomAD v2.1 non-cancer: absent; gnomAD v3.1 non-cancer: absent; regional average read depth: not reported.
  • The four on-record VCEP files were searched under c.598A>G, p.Thr200Ala, and p.T200A; none contained a variant-specific row.
Still missing
  • Required PM2 regional average read depth (at least 25) is not reported in the available gnomAD evidence.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in HUMU-40-1557-s001.xlsx.
Sources
PM3 VCEPNot assessed: no documented Fanconi Anemia phenotype with a same-gene pathogenic/likely pathogenic co-occurring variant and qualifying phase or homozygous observation was available. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 VCEP limits PM3 to a patient with a phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia and co-occurrent variants in the same gene. The case evidence does not document a qualifying Fanconi Anemia phenotype, a same-gene pathogenic/likely pathogenic co-occurring variant, or phase/homozygous status for NM_000059.4:c.598A>G. Consequently, the Table 6 point assignment cannot be evaluated and no PM3 strength can be assigned. The variant was searched in Specifications_V1.2_2024-11-18.docx.txt under c.598A>G, p.Thr200Ala, and p.T200A; no variant-specific PM3 entry was found.

VCEP rule
For recessive disorders, detected in trans with a pathogenic variant. ... Apply for patient with phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia (FA), and co-occurrent variants in the same gene. ... See Table 6 for approach to assign points per proband, and final PM3 code assignment based on the sum of PM3-related points. ... PM3_Strong = 4 (or more) points; PM3 = 2 points; PM3_Supporting = 1 point.
Evidence considered
  • Specifications_V1.2_2024-11-18.docx.txt, Table 1 PM3_VariableWeight: PM3 applies for a patient with phenotype consistent with BRCA1- or BRCA2-related Fanconi Anemia and co-occurrent variants in the same gene; the co-occurrent variant must be classified as pathogenic or likely pathogenic using VCEP specifications.
  • Specifications_V1.2_2024-11-18.docx.txt, Table 6: PM3 assigns 2 points for a pathogenic/likely pathogenic variant in trans or homozygote with a phenotype consistent with Fanconi Anemia, and 1 point when phase is unknown; final PM3 strength requires PM3_Supporting = 1 point, PM3 = 2 points, or PM3_Strong = 4 or more points.
  • The case evidence contains no documented qualifying Fanconi Anemia phenotype, same-gene pathogenic/likely pathogenic co-occurring variant, or phase/homozygous observation for NM_000059.4:c.598A>G.
Still missing
  • No qualifying Fanconi Anemia phenotype, same-gene pathogenic/likely pathogenic co-occurring variant, or phase/homozygous observation is documented for this variant.
  • No variant-specific PM3 entry was found in Specifications_V1.2_2024-11-18.docx.txt after searching c.598A>G, p.Thr200Ala, and p.T200A.
Sources
PP1 VCEPNot assessed: no quantitative co-segregation LR is available, and the available clinical-history LR is 1.277769323983238 rather than a segregation measure. Details ▾Hide ▴
Reasoning

PP1 requires co-segregation with disease in multiple affected family members evaluated by a quantitative Bayes-score method. The available case evidence contains no proband-level segregation observations, parental testing, affected-relative genotypes, meioses, pedigree data, or quantitative co-segregation LR for NM_000059.4:c.598A>G (p.Thr200Ala/p.T200A). Li et al. 2020 Supplementary Table 4 has a clinical-history LR row for BRCA2 c.598A>G (LOG(LR)=0.1064524576067924, N_Probands=1, LR=1.277769323983238), but this is a personal/family-history clinical-history LR rather than a co-segregation LR and the source guidance states it must not be used alone for PP1 or segregation. Therefore PP1 cannot be assessed from the available evidence; no PP1 strength is assigned.

VCEP rule
Co-segregation with disease in multiple affected family members See Appendix I Apply weight as per Bayes Score: PP1 - LR ≥2.08:1 PP1_Moderate – LR≥4.3:1 PP1_Strong – LR≥18.7:1 PP1_Very Strong – LR≥350:1
Evidence considered
  • ClinGen ENIGMA BRCA2 specification v1.2, PP1_VariableWeight: PP1 is based on co-segregation with disease in multiple affected family members and is weighted by a quantitative Bayes-score LR; no case-specific co-segregation LR was available.
  • Li et al. 2020 Supplementary Table 4, BRCA2 c.598A>G row: LOG(LR)=0.1064524576067924, N_Probands=1, LR=1.277769323983238. This is a clinical-history LR, not a segregation LR, and was not used to assign PP1.
  • The governing VCEP files were searched under c.598A>G, p.Thr200Ala, and p.T200A; no variant-specific PP1 segregation record was found in Specifications_V1.2_2024-11-18.docx, SupplementaryTables_V1.2_2024-11-18.xlsx, or HUMU-40-1557-s001.xlsx.
Still missing
  • No quantitative co-segregation analysis for NM_000059.4:c.598A>G, including affected-relative genotypes, meioses, or a Bayes-score LR.
  • No proband-level phenotype and segregation records or parental testing results are available.
  • Specifications_V1.2_2024-11-18.docx was searched for c.598A>G, p.Thr200Ala, and p.T200A; no variant-specific PP1 entry was found.
  • SupplementaryTables_V1.2_2024-11-18.xlsx was searched for c.598A>G, p.Thr200Ala, and p.T200A; no entry was found.
  • HUMU-40-1557-s001.xlsx was searched for c.598A>G, p.Thr200Ala, and p.T200A; no entry was found.
Sources
BS2 VCEPNot assessed: gnomAD reports 0 homozygotes, but no qualifying healthy-adult or phenotyped-cohort BS2 observation with VCEP points is available. Details ▾Hide ▴
Reasoning

The ENIGMA VCEP requires observation in a healthy adult and assigns BS2 strength from points based on qualifying clinical or research-cohort observations, including specified co-occurrence or homozygous observations and absence of Fanconi Anemia features. The available population data show 0 homozygotes, and no qualifying healthy-adult or phenotyped cohort observation is provided. The VCEP expressly excludes using gnomAD frequency-code data for BS2. Therefore BS2 cannot be assessed from the available evidence.

VCEP rule
Applied in absence of features of recessive disease, namely Fanconi Anemia phenotype. See **Specifications Table 8** for additional stipulations, and approach to assign points per proband, and final BS2 code assignment based on the sum of BS2-related points. See Appendix H for additional details.
Evidence considered
  • ENIGMA BS2 rule: applied in the absence of features of recessive disease, namely Fanconi Anemia phenotype; Table 8 determines points and final code assignment.
  • ENIGMA Appendix H states BS2 is for qualifying clinical or research-cohort observations and is not to be applied to frequency-based data; gnomAD observations of at least two homozygotes are already captured by BA1 or BS1.
  • gnomAD v4.1: 0 homozygotes; no qualifying healthy-adult or phenotyped-cohort observation was supplied.
  • The four on-record VCEP files were searched under c.598A>G, p.Thr200Ala, and p.T200A; none contained a variant-specific row.
Still missing
  • No qualifying healthy-adult or phenotyped clinical/research-cohort observation, phase information, age/follow-up, or Fanconi Anemia assessment was available for BS2 point assignment.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-specific entry for c.598A>G, p.Thr200Ala, or p.T200A was found in HUMU-40-1557-s001.xlsx.
Sources
BS3 VCEPNot assessed: no calibrated benign protein-function result specific to c.598A>G or p.(Thr200Ala) was found in the governing VCEP sources. Details ▾Hide ▴
Reasoning

BS3 cannot be assessed from the available VCEP-governed evidence. The governing ENIGMA rule requires well-established in vitro or in vivo studies showing no damaging effect on protein function, measured through protein, or mRNA and protein combined, with calibrated assay recommendations in Table 9. Exact-variant searches for c.598A>G, p.Thr200Ala, and p.T200A found no row in Specifications_Table9_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, HUMU-40-1557-s001.xlsx, or SupplementaryTables_V1.2_2024-11-18.xlsx. Table 9 contains a different same-position variant, c.599C>T p.(Thr200Ile), and the extracted functional paper PMID:29988080 explicitly does not mention c.598A>G or p.(T200A); neither can be transferred to this variant. No calibrated benign functional result specific to c.598A>G is therefore available to apply BS3.

VCEP rule
Well-established in vitro or in vivo functional studies shows no damaging effect on protein function. Assay measures effect via protein only OR mRNA and protein combined. See Specifications Table 9 for code recommendations from calibrated published assays. Also see Figure1C and Appendix E for details.
Evidence considered
  • Specifications_Table9_V1.2_2024-11-18.xlsx, sheet Table9_BRCA12VCEP_specs: exact-notation searches for c.598A>G, p.Thr200Ala, and p.T200A returned no row; the table states that additional published assay results must be reviewed under Figure 1C before PS3 or BS3 application.
  • Specifications_Table9_V1.2_2024-11-18.xlsx, sheet Table9_BRCA12VCEP_specs: c.599C>T p.(Thr200Ile) is a different variant and is not evidence for c.598A>G p.(Thr200Ala).
  • PMID:29988080 paper_extracts entry: the mESC complementation, HDR, cisplatin, and PARP-inhibitor assay paper does not mention c.598A>G or p.(T200A), so it supplies no variant-specific benign result.
  • The governing ENIGMA BS3 rule requires a well-established no-damaging functional study measured via protein or combined mRNA and protein; the required variant-specific calibrated result is unavailable.
Still missing
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Specifications_Table9_V1.2_2024-11-18.xlsx, the ENIGMA curated functional-assay table.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in HUMU-40-1557-s001.xlsx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • The available functional paper PMID:29988080 describes a BRCA2 assay but its extracted finding states that c.598A>G and p.(T200A) are not mentioned; no variant-specific assay result is available from that paper.
Sources
BS4 VCEPNot assessed: no variant-specific quantitative non-segregation LR or affected-family-member data are available to compare with the VCEP's supporting threshold of LR ≤0.48:1. Details ▾Hide ▴
Reasoning

The VCEP requires lack of segregation in affected family members measured by a quantitative co-segregation method and assigns strength from the Bayes-score likelihood ratio: supporting at LR ≤0.48:1, moderate at LR ≤0.23:1, strong at LR ≤0.05:1, and very strong at LR ≤0.00285:1. The case evidence bundle contains no variant-specific proband, pedigree, parental-testing, meiosis, affected-relative, non-segregation, or quantitative co-segregation result for c.598A>G, so BS4 cannot be assessed without substituting unsupported assumptions.

VCEP rule
Lack of segregation in affected members of a family. See Appendix I. Apply weight as per Bayes Score: BS4_Supporting - LR ≤0.48 to &gt;0.23:1 BS4_Moderate - LR ≤0.23:1 BS4 - LR ≤0.05:1 BS4_Very strong – LR ≤0.00285:1
Evidence considered
  • Specifications V1.2 Table 1, BS4 row: lack of segregation in affected family members is evaluated using a quantitative co-segregation method and Bayes-score thresholds of LR ≤0.48:1 for BS4_Supporting, LR ≤0.23:1 for BS4_Moderate, LR ≤0.05:1 for BS4, and LR ≤0.00285:1 for BS4_Very strong.
  • The case bundle provides no variant-specific segregation or non-segregation observation and no quantitative LR for NM_000059.4:c.598A>G.
Still missing
  • No variant-specific proband, pedigree, parental-testing, meiosis, affected-relative, non-segregation, or quantitative co-segregation result is available in the case evidence bundle.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in SupplementaryTables_V1.2_2024-11-18.xlsx.txt.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in HUMU-40-1557-s001.xlsx.txt.
Sources
BP7 VCEPNot assessed: BP7_Strong (RNA) covers missense variants outside domains but requires a qualifying mRNA-only assay, which is unavailable for p.Thr200Ala. Details ▾Hide ▴
Reasoning

The ordinary BP7 supporting routes are for silent variants inside a clinically important domain or intronic variants outside conserved donor/acceptor motif positions, so they do not cover this missense variant. The VCEP also repurposes BP7 as BP7_Strong (RNA) for missense/in-frame variants outside a clinically important domain, but that route requires a well-established in vitro or in vivo mRNA-only assay showing no damaging effect. No qualifying mRNA assay result for c.598A>G / p.Thr200Ala is available in the reviewed case evidence or governing variant-level tables. SpliceAI max delta 0.073 alone cannot satisfy the BP7_Strong (RNA) functional-assay requirement.

VCEP rule
Well-established in vitro or in vivo functional studies shows no damaging effect on protein function as measured by effect on mRNA transcript profile – mRNA assay only. ... Apply as BP7_Strong (RNA) for intronic, silent, and missense/in-frame variants located outside a (potentially) clinically important functional domain. ... As justified in the appendices, (potentially) clinically important functional domains are defined as: BRCA2 PALB2 binding domain aa 10-40; BRCA2 DNA binding aa 2481-3186.
Evidence considered
  • The VCEP BP7 ordinary supporting routes are limited to silent or intronic variants, whereas this variant is missense.
  • The VCEP BP7_Strong (RNA) route includes missense variants outside a clinically important functional domain but requires a well-established mRNA-only functional study; no such variant-specific result was found.
  • SpliceAI maximum delta score is 0.073, but a no-impact splice prediction is not a substitute for the required mRNA-only functional assay under BP7_Strong (RNA).
Still missing
  • No qualifying mRNA-only functional assay result for c.598A>G, p.Thr200Ala, or p.T200A was identified in the case evidence or SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-level BP7 entry was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-level BP7 entry was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-level BP7 entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.
Sources
Not applicable · 13· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.598A>G is a missense substitution, whereas ENIGMA PVS1 applies to null variants such as nonsense, frameshift, canonical splice-site, initiation-codon, or exon-deletion variants. Details ▾Hide ▴
Reasoning

NM_000059.4:c.598A>G is a missense variant, NP_000050.3:p.(Thr200Ala), in exon 7. The ENIGMA PVS1 rule is limited to null variants (nonsense, frameshift, canonical donor/acceptor splice-site, initiation-codon, or single/multi-exon deletion) and does not include ordinary missense substitutions. Therefore PVS1 is not applicable; no PVS1 strength tier is assigned. The governing Specifications, Appendices, Table 4, and Houdayer files contained no entry for c.598A>G, p.Thr200Ala, or p.T200A.

VCEP rule
Null variant (nonsense, frameshift, splice site (donor/acceptor +/−1,2), initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease. Apply at appropriate strength according to PVS1 flowchart, which considers knowledge of clinically important functional domains. See Specifications Table 4 and Appendix D for details.
Evidence considered
  • Case variant consequence: NM_000059.4:c.598A>G, NP_000050.3:p.(Thr200Ala)/p.(T200A), missense, exon 7.
  • ENIGMA Specifications v1.2 PVS1 rule applies to null variants and directs application according to the PVS1 flowchart; the missense variant is outside that named variant set.
  • Specifications Table 4 is an exon-organized table for initiation, nonsense/frameshift, deletion, duplication, and canonical splice-site variants; it has no row for this missense variant.
Still missing
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_Table4_V1.2_2024-11-18.xlsx.txt.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
PS2 VCEPNot applicable: the BRCA2 VCEP explicitly says not to use PS2 because de novo occurrences lack calibrated predictive capacity for relatively common BRCA1/2-related cancers. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 VCEP explicitly instructs that PS2 is not used for BRCA1/2-related cancers because these cancers occur relatively commonly and the predictive capacity of de novo occurrences has not been calibrated. This criterion is therefore not applicable regardless of whether a de novo observation is available.

VCEP rule
De novo (paternity confirmed) in a patient with the disease and no family history. ... Do not use ... BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • Specifications V1.2 Table 1, PS2 row: de novo occurrence with confirmed paternity is listed, followed by the pre-assigned specification 'Do not use' because BRCA1/2-related cancers occur relatively commonly and de novo predictive capacity is uncalibrated.
Sources
PM1 VCEPNot applicable: ENIGMA designates PM1 N/A, and residue 200 lies outside its BRCA2 domains at aa 10-40 and aa 2481-3186. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification explicitly assigns PM1 as not applicable and directs domain-related missense evidence to BP1, BP4, and PP3. The case-specific vcep_materials.json domain_tables object is empty. Independently, residue 200 is outside the VCEP-defined BRCA2 PALB2-binding domain (aa 10-40) and DNA-binding domain (aa 2481-3186), and no VCEP-named hotspot route applies.

VCEP rule
N/A. Informed by clinically calibrated bioinformatic prior probability of pathogenicity for missense alterations – missense predictions only apply if a variant is located in a (potentially) clinically important functional domain. Evaluate under BP1, BP4, PP3.
Evidence considered
  • vcep_materials.json: domain_tables is empty for BRCA2.
  • Specifications_V1.2_2024-11-18.docx, Table 16: PM1 is N/A and is evaluated through BP1, BP4, and PP3.
  • Specifications_V1.2_2024-11-18.docx and Appendix J define the BRCA2 potentially clinically important domains as PALB2 binding aa 10-40 and DNA binding aa 2481-3186; p.Thr200 is outside both.
  • No VCEP-defined hotspot or approved critical-domain entry covering residue 200 was found.
Sources
PM4 VCEPNot applicable: PM4 is restricted by ENIGMA to in-frame insertion/deletion protein-length changes or stop-loss variants, not the c.598A>G missense substitution. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification explicitly defines PM4 for protein-length changes caused by in-frame deletions/insertions in a non-repeat region or stop-loss variants, then states that it is not to be used. This variant is a missense substitution, not an in-frame indel or stop-loss variant; PM4 is therefore not applicable.

VCEP rule
Protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants. Do not use
Evidence considered
  • ENIGMA Specifications v1.2 PM4 entry: protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss variants; the same entry states 'Do not use'.
  • Case variant consequence is missense, with no protein-length change, in-frame insertion/deletion, or stop-loss consequence.
Still missing
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_V1.2_2024-11-18.docx.txt.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Appendices_V1.2_2024-11-18.docx.txt.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in Specifications_Table4_V1.2_2024-11-18.xlsx.txt.
  • No entry for c.598A>G, p.Thr200Ala, or p.T200A was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.txt.
Sources
PM5 N/ANot applicable: ENIGMA excludes classic missense PM5 and limits its repurposed form to pathogenic PTC comparisons, whereas c.598A>G is missense. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification explicitly states that classic missense PM5 is not used and is considered through BP1, BP4, and PP3. Its PM5 repurposing is limited to protein termination codon variants in an exon with a different proven pathogenic PTC; c.598A>G is a missense variant in exon 7, not a PTC. Although the VCEP supplementary material contains the alternate same-residue p.Thr200Ile (c.599C>T) as a no-functional-impact reference-set variant, it cannot activate the VCEP PM5 rule.

VCEP rule
N/A. Some residues can harbor pathogenic and non-pathogenic substitutions. Evaluate under BP1, BP4, PP3.
Evidence considered
  • Specifications_V1.2_2024-11-18.docx, Table 16: classic missense PM5 is N/A and is evaluated under BP1, BP4, and PP3.
  • Specifications_V1.2_2024-11-18.docx: PM5_VariableWeight (PTC) is for a protein termination codon variant in an exon where a different proven pathogenic PTC variant has been seen before.
  • SupplementaryTables_V1.2_2024-11-18.xlsx, reference-set rows: BRCA2 c.599C>T, p.(Thr200Ile), is listed as No functional impact; it is not a proven pathogenic comparator.
Sources
PM6 VCEPNot applicable: the BRCA2 VCEP explicitly says not to use PM6 because de novo occurrences lack calibrated predictive capacity for relatively common BRCA1/2-related cancers. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 VCEP explicitly instructs that PM6 is not used for BRCA1/2-related cancers because these cancers occur relatively commonly and the predictive capacity of de novo occurrences has not been calibrated. This criterion is therefore not applicable regardless of whether parental testing without confirmed maternity and paternity is available.

VCEP rule
Confirmed de novo without confirmation of paternity and maternity. ... Do not use ... BRCA1/2-related cancers occur relatively commonly. No information to calibrate the predictive capacity of de novo occurrences.
Evidence considered
  • Specifications V1.2 Table 1, PM6 row: confirmed de novo without confirmation of paternity and maternity is listed, followed by the pre-assigned specification 'Do not use' because BRCA1/2-related cancers occur relatively commonly and de novo predictive capacity is uncalibrated.
Sources
PP2 VCEPNot applicable: ENIGMA states missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA1/2 specification explicitly marks PP2 as not applicable because missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.

VCEP rule
N/A. Missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.
Evidence considered
  • Specifications_V1.2_2024-11-18.docx, Table 16: PP2 is N/A because missense variants are not a common mechanism of pathogenicity for BRCA1 and BRCA2.
Sources
PP4 N/ANot applicable: Li et al. clinical-history LR 1.27777 is below the VCEP PP4 supporting threshold, 1.27777 ≥ 2.08? no. Details ▾Hide ▴
Reasoning

The ENIGMA clinical-history table contains BRCA2 c.598A>G with LOG(LR)=0.1064524576067924 and LR=1.277769323983238. The VCEP PP4 rule requires LR ≥2.08 for supporting evidence, and explicitly states that combined LR 1.00 to <2.08 is not informative and PP4 is not applicable. The required comparison is 1.277769323983238 ≥ 2.08? no.

VCEP rule
Breast cancer is very common and has a high degree of genetic heterogeneity (caused by pathogenic variants in numerous genes). Use ONLY to capture combined LR towards pathogenicity, based on multifactorial likelihood clinical data. ... PP4 - LR ≥2.08:1 ... Combined LR 1.00 to <2.08 is not informative (PP4 not applicable).
Evidence considered
  • Li et al. 2020 BRCA2 clinical-history LR table, exact row BRCA2 c.598A>G: LOG(LR)=0.1064524576067924, N_Probands=1, LR=1.277769323983238.
  • The VCEP PP4 rule states: PP4 - LR ≥2.08:1; Combined LR 1.00 to <2.08 is not informative (PP4 not applicable).
  • Explicit threshold comparison: 1.277769323983238 ≥ 2.08? no.
Sources
PP5 VCEPNot applicable: the ENIGMA specification explicitly says PP5 is not to be used for this VCEP framework. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification states that PP5 should not be used. ClinVar lists this variant as uncertain significance and provides no usable expert-panel pathogenic assertion; the literature packet and available extracts do not provide a verified variant-specific pathogenic report that could alter the VCEP rule.

VCEP rule
Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation. ... Do not use
Evidence considered
  • The ENIGMA specification's PP5 entry is: Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation; Do not use.
  • Case ClinVar summary: Uncertain significance, five clinical-laboratory submissions, zero expert-panel submissions.
Sources
BP2 VCEPNot applicable: ENIGMA explicitly says BP2 is not used and applies it only in the context of BS2. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 VCEP explicitly states that BP2 is not to be used and is applied only in the context of BS2. Therefore, phase, cis/trans observations, and co-occurrence data cannot produce a BP2 assertion under this VCEP framework. The variant was searched in Specifications_V1.2_2024-11-18.docx.txt under c.598A>G, p.Thr200Ala, and p.T200A; no variant-specific BP2 entry was found.

VCEP rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder, or observed in cis with a pathogenic variant in any inheritance pattern ... Do not use ... Applied only in the context of BS2.
Evidence considered
  • Specifications_V1.2_2024-11-18.docx.txt, Table 1 BP2: the criterion is listed as observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern, but the VCEP specification says "Do not use" and "Applied only in the context of BS2."
Still missing
  • No variant-specific BP2 entry was found in Specifications_V1.2_2024-11-18.docx.txt after searching c.598A>G, p.Thr200Ala, and p.T200A.
Sources
BP3 VCEPNot applicable: BP3 is restricted to in-frame deletions/insertions, whereas c.598A>G causes the missense substitution p.(Thr200Ala). Details ▾Hide ▴
Reasoning

BP3 is not applicable under the ClinGen ENIGMA BRCA2 VCEP specification: the governing entry states, "In-frame deletions/insertions in a repetitive region without a known function" and "Do not use". This variant is NM_000059.4:c.598A>G, NP_000050.3:p.(Thr200Ala) / p.(T200A), a missense substitution rather than an in-frame deletion or insertion, so BP3 cannot apply. The exact variant notations were searched in Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, Specifications_Table4_V1.2_2024-11-18.xlsx, and PMID_22505045_Houdayer_2012_HumMutat.pdf; no variant-specific BP3 entry was found, but no such entry is required because the VCEP marks BP3 as not applicable.

VCEP rule
In-frame deletions/insertions in a repetitive region without a known function Do not use
Evidence considered
  • ENIGMA CSPEC BP3 entry: applicability is Not Applicable.
  • Specifications_V1.2_2024-11-18.docx, Table 1 BP3 row: ‘In-frame deletions/insertions in a repetitive region without a known function’ followed by ‘Do not use’; the same row states that the evidence is captured by bioinformatic tool prediction and domain analysis.
  • Case consequence evidence: NM_000059.4:c.598A>G is a missense variant producing NP_000050.3:p.(Thr200Ala) / p.(T200A), not an in-frame deletion or insertion.
Still missing
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Specifications_V1.2_2024-11-18.docx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Appendices_V1.2_2024-11-18.docx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in Specifications_Table4_V1.2_2024-11-18.xlsx.
  • No exact c.598A>G, p.Thr200Ala, or p.T200A entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.
Sources
BP4 N/ANot applicable: p.Thr200Ala is a missense variant outside both ENIGMA-defined BRCA2 functional domains covered by the BP4 missense rule. Details ▾Hide ▴
Reasoning

The VCEP BP4 missense route is limited to missense or in-frame variants inside a clinically important functional domain and requires both no predicted protein impact and SpliceAI <=0.1. p.Thr200Ala is outside both VCEP-defined BRCA2 domains, so that route is not applicable. The other BP4 routes cover silent variants inside a domain or intronic variants outside canonical donor/acceptor +/-1,2 positions; this variant is neither silent nor intronic. The available SpliceAI maximum delta of 0.073 does not create an applicable BP4 route for this missense variant outside the defined domains.

VCEP rule
Apply BP4 for: ... Missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain, and no predicted impact via protein change or splicing (BayesDel predicted No Impact AND SpliceAI ≤0.1). ... Silent variant inside a (potentially) clinically important functional domain, if no predicted impact via splicing (SpliceAI ≤0.1). ... Intronic variants outside of the donor and acceptor ±1,2 positions AND no predicted impact via splicing (SpliceAI ≤0.1). ... As justified in the appendices, (potentially) clinically important functional domains are defined as: BRCA2 PALB2 binding domain aa 10-40; BRCA2 DNA binding aa 2481-3186.
Evidence considered
  • The VCEP defines the BRCA2 clinically important domains as PALB2 binding aa 10-40 and DNA binding aa 2481-3186; residue 200 is outside both domains.
  • The VCEP BP4 missense route requires a variant inside a clinically important domain plus BayesDel no-impact and SpliceAI <=0.1; the location prerequisite is not satisfied. SpliceAI maximum delta was 0.073 and BayesDel no-AF score was -0.203159, but these values cannot establish BP4 outside the route's defined missense scope.
Sources
BP6 VCEPNot applicable: the ENIGMA specification explicitly says BP6 is not to be used for this VCEP framework. Details ▾Hide ▴
Reasoning

The ENIGMA BRCA2 specification states that BP6 should not be used. No independent benign assertion can override this VCEP-specific instruction.

VCEP rule
Reputable source recently reports variant as benign but the evidence is not available to the laboratory to perform an independent evaluation. ... Do not use
Evidence considered
  • The ENIGMA specification's BP6 entry is: Reputable source recently reports variant as benign but the evidence is not available to the laboratory to perform an independent evaluation; Do not use.
Sources

Identifiers

Gene
BRCA2
Transcript
NM_000059.4
Coding (HGVS c.)
NM_000059.4:c.598A>G
Protein (HGVS p.)
NP_000050.3:p.(Thr200Ala)
GRCh38
chr13:32326580 A>G
GRCh37
chr13:32900717 A>G
Location and type
Exon 7 · missense
ClinVar
91432

Gene diagram

Every interpreted variant in BRCA2, mapped onto the exon structure of NM_000059.4. Select a row to find it on the plot.

BRCA2NM_000059.4
Fetching transcript structure from UCSC…
gnomAD v4.1 13 / 1,611,912 alleles AF 8.06e-06 · 0 homozygotes · FAF 6.16e-06
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 8.1e-06 · 13 / 1,611,912 alleles · 0 hom · FAF 6.2e-06
European (non-Finnish)13 / 1,177,970 1.1e-05
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 8.06496e-06; MAF= 0.00081%, 13/1611912 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 1.10359e-05; MAF= 0.00110%, 13/1177970 alleles, homozygotes = 0); grpmax FAF= 6.16e-06.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -306 bp
0.000
SpliceAI acceptor gainat -81 bp
0.053
SpliceAI donor lossat -37 bp
0.001
SpliceAI donor gainat +33 bp
0.073
Pangolin splice lossmagnitude shown
-0.006
Pangolin splice gain
0.086

Other predictors

REVEL
0.225
BayesDel
-0.203

How the predictions were used

PP3 VCEPNot met: SpliceAI maximum delta 0.073 is below the ENIGMA PP3 splicing threshold of 0.2 for missense variants. Details ▾Hide ▴
Reasoning

The variant is missense at p.Thr200Ala and lies outside the VCEP-defined BRCA2 clinically important domains (PALB2-binding aa 10-40 and DNA-binding aa 2481-3186), so the PP3 protein-impact route does not apply. The applicable PP3 splicing route covers missense variants irrespective of domain location, but requires SpliceAI >=0.2; the observed maximum delta score is 0.073 (DS_DG 0.073), therefore the splicing prediction does not meet PP3. No pre-assigned PP3 code or variant-level entry was found for c.598A>G, p.Thr200Ala, or p.T200A in SupplementaryTables_V1.2_2024-11-18.xlsx, Specifications_V1.2_2024-11-18.docx, Appendices_V1.2_2024-11-18.docx, or PMID_22505045_Houdayer_2012_HumMutat.pdf.

VCEP rule
Do not apply PP3 if PVS1 is met at any strength. ... Apply PP3 for missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain and predicted impact via protein change (BayesDel predicted Impact). ... Apply PP3 for predicted splicing (SpliceAI ≥0.2) for silent, missense/in-frame (irrespective of location in clinically important functional domain) and for intronic variants outside of the donor and acceptor ±1,2 positions.
Evidence considered
  • NM_000059.4:c.598A>G is a missense variant encoding NP_000050.3:p.(Thr200Ala), outside the VCEP-defined BRCA2 PALB2-binding domain aa 10-40 and DNA-binding domain aa 2481-3186; the PP3 protein-impact route therefore does not apply.
  • SpliceAI lookup for NM_000059.4:c.598A>G: DS_AG=0.053, DS_AL=0.000, DS_DG=0.073, DS_DL=0.001; maximum delta score=0.073, below the VCEP PP3 threshold of >=0.2 for predicted splicing.
Still missing
  • No variant-level PP3 pre-assignment was found in SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-level PP3 entry was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-level PP3 entry was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-level PP3 entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.
Sources
BP7 VCEPNot assessed: BP7_Strong (RNA) covers missense variants outside domains but requires a qualifying mRNA-only assay, which is unavailable for p.Thr200Ala. Details ▾Hide ▴
Reasoning

The ordinary BP7 supporting routes are for silent variants inside a clinically important domain or intronic variants outside conserved donor/acceptor motif positions, so they do not cover this missense variant. The VCEP also repurposes BP7 as BP7_Strong (RNA) for missense/in-frame variants outside a clinically important domain, but that route requires a well-established in vitro or in vivo mRNA-only assay showing no damaging effect. No qualifying mRNA assay result for c.598A>G / p.Thr200Ala is available in the reviewed case evidence or governing variant-level tables. SpliceAI max delta 0.073 alone cannot satisfy the BP7_Strong (RNA) functional-assay requirement.

VCEP rule
Well-established in vitro or in vivo functional studies shows no damaging effect on protein function as measured by effect on mRNA transcript profile – mRNA assay only. ... Apply as BP7_Strong (RNA) for intronic, silent, and missense/in-frame variants located outside a (potentially) clinically important functional domain. ... As justified in the appendices, (potentially) clinically important functional domains are defined as: BRCA2 PALB2 binding domain aa 10-40; BRCA2 DNA binding aa 2481-3186.
Evidence considered
  • The VCEP BP7 ordinary supporting routes are limited to silent or intronic variants, whereas this variant is missense.
  • The VCEP BP7_Strong (RNA) route includes missense variants outside a clinically important functional domain but requires a well-established mRNA-only functional study; no such variant-specific result was found.
  • SpliceAI maximum delta score is 0.073, but a no-impact splice prediction is not a substitute for the required mRNA-only functional assay under BP7_Strong (RNA).
Still missing
  • No qualifying mRNA-only functional assay result for c.598A>G, p.Thr200Ala, or p.T200A was identified in the case evidence or SupplementaryTables_V1.2_2024-11-18.xlsx.
  • No variant-level BP7 entry was found in Specifications_V1.2_2024-11-18.docx.
  • No variant-level BP7 entry was found in Appendices_V1.2_2024-11-18.docx.
  • No variant-level BP7 entry was found in PMID_22505045_Houdayer_2012_HumMutat.pdf.
Sources
BP4 N/ANot applicable: p.Thr200Ala is a missense variant outside both ENIGMA-defined BRCA2 functional domains covered by the BP4 missense rule. Details ▾Hide ▴
Reasoning

The VCEP BP4 missense route is limited to missense or in-frame variants inside a clinically important functional domain and requires both no predicted protein impact and SpliceAI <=0.1. p.Thr200Ala is outside both VCEP-defined BRCA2 domains, so that route is not applicable. The other BP4 routes cover silent variants inside a domain or intronic variants outside canonical donor/acceptor +/-1,2 positions; this variant is neither silent nor intronic. The available SpliceAI maximum delta of 0.073 does not create an applicable BP4 route for this missense variant outside the defined domains.

VCEP rule
Apply BP4 for: ... Missense or in-frame insertion, deletion or delins variants inside a (potentially) clinically important functional domain, and no predicted impact via protein change or splicing (BayesDel predicted No Impact AND SpliceAI ≤0.1). ... Silent variant inside a (potentially) clinically important functional domain, if no predicted impact via splicing (SpliceAI ≤0.1). ... Intronic variants outside of the donor and acceptor ±1,2 positions AND no predicted impact via splicing (SpliceAI ≤0.1). ... As justified in the appendices, (potentially) clinically important functional domains are defined as: BRCA2 PALB2 binding domain aa 10-40; BRCA2 DNA binding aa 2481-3186.
Evidence considered
  • The VCEP defines the BRCA2 clinically important domains as PALB2 binding aa 10-40 and DNA binding aa 2481-3186; residue 200 is outside both domains.
  • The VCEP BP4 missense route requires a variant inside a clinically important domain plus BayesDel no-impact and SpliceAI <=0.1; the location prerequisite is not satisfied. SpliceAI maximum delta was 0.073 and BayesDel no-AF score was -0.203159, but these values cannot establish BP4 outside the route's defined missense scope.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.07). REVEL score = 0.225. BayesDel score = -0.203159.

6 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata. None of the listed paper records explicitly indicates that the variant is named.

Recorded publications

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
    No paper-specific finding is recorded.
    PMID 25741868 ↗
  • Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
    No paper-specific finding is recorded.
    PMID 31672839 ↗
  • The emerging landscape of breast cancer susceptibility.
    Stratton MR et al. · 2008
    No paper-specific finding is recorded.
    PMID 18163131 ↗
  • BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.
    Adam MP et al. · 1993
    No paper-specific finding is recorded.
    PMID 20301425 ↗
  • ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
    Green RC et al. · 2013
    The paper does not mention BRCA2 or c.598A>G/p.(T200A); it provides general ACMG recommendations and no variant-specific clinical, case-control, segregation, or population evidence.
    Does not name this variant
    PMID 23788249 ↗
    Quoted passage
    For most genes, only variants that have been previously reported and are a recognized cause of the disorder or variants that are previously unreported but are of the type which is expected to cause the disorder have been recommended for analysis and reporting.

    Recommendations; Discussion

  • American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
    No paper-specific finding is recorded.
    PMID 26324357 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 8.06496e-06; MAF= 0.00081%, 13/1611912 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 1.10359e-05; MAF= 0.00110%, 13/1177970 alleles, homozygotes = 0); grpmax FAF= 6.16e-06.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (5 clinical laboratories). (ClinVarID = 91432)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.07). REVEL score = 0.225. BayesDel score = -0.203159.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. BRCA2, a tumor suppressor involved in the DNA damage response, is mutated in various cancer types.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.